Posted by Michael Wonder on 19 Jun 2020
Cancer Prevention Pharmaceuticals submits EU marketing authorisation application for CPP-1X/sul for treatment of familial adenomatous polyposis
18 June 2020 - Cancer Prevention Pharmaceuticals announced today that it has submitted a marketing authorisation application to the European Medicines Agency for CPP-1X/sul for treatment of adults with familial adenomatous polyposis.
CPP also plans to submit a new drug application to the U.S. Food and Drug Administration this month seeking accelerated approval for CPP-IX/sul for the same indication.
CPP-1X/sul is a combination of CPP-1X (eflornithine) and sulindac (CPP-1X/sul).
